Itraconazole vs. trimethoprim-sulfamethoxazole: A comparative cohort study of 200 patients with paracoccidioidomycosis

Medical Mycology

Volumn 52, Issue 3, 2014, Pages 303-310

  Borges, Sheila Rocha Conceição ^a   Da Silva, Gilberto Marcelo Sperandio ^a   Da Costa Chambela, Mayara ^a   De Vasconcellos De, C Raquel Oliveira ^a   Costa, Regina Lana Braga ^a   Wanke, Bodo ^a   Do Valle, Antonio Carlos Francesconi ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

itraconazole; Paracoccidioidomycosis; treatment; trimethoprim sulfamethoxazole (TMP SMX)

Indexed keywords

COTRIMOXAZOLE; ITRACONAZOLE;

ADULT; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONVALESCENCE; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; RETROSPECTIVE STUDY; SMOKING; SOUTH AMERICAN BLASTOMYCOSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME;

ITRACONAZOLE; PARACOCCIDIOIDOMYCOSIS; TREATMENT; TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX);

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BRAZIL; COHORT STUDIES; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; PARACOCCIDIOIDOMYCOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; YOUNG ADULT;

EID: 84898907021     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myt012     Document Type: Article

References (32)

1. Restrepo A. The ecology of Paracoccidioides brasiliensis: A puzzle still unsolved. Sabouraudia 1985; 23: 323-334.
2. Francesconi F, da SilvaMT, Costa RL et al. Long-term outcome of neuroparacoccidioidomycosis treatment. Rev Soc Bras Med Trop 2011; 44: 22-25.
3. Martinez R. Paracoccidioidomycosis: The dimension of the problem of a neglected disease. Rev Soc Bras Med Trop 2010; 43: 480.
4. Coutinho ZF, Silva D, Lazera M et al. Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad Saude Publica 2002; 18: 1441-1454.
5. Barrozo LV, Benard G, Silva ME et al. First description of a cluster of acute/subacute paracoccidioidomycosis cases and its association with a climatic anomaly. PLoS Negl Trop Dis 2010; 4: 643.
6. Moreto TC, Marques ME, de Oliveira ML et al. Accuracy of routine diagnostic tests used in paracoccidioidomycosis patients at a university hospital. Trans R Soc Trop Med Hyg 2011; 105: 473-478.
7. Bellissimo-Rodrigues F, Bollela VR, Da Fonseca BA,Martinez R. Endemic paracoccidioidomycosis: Relationship between clinical presentation and patients? demographic features. Med Mycol 2013; 51: 313-318.
8. Wanke B, Aid?eMA. Chapter 6-Paracoccidioidomycosis. J Bras Pneumol 2009; 35: 1245-1249.
9. Diaz M, Negroni R, Montero-Gei F et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis 1992; 14: S68-S76.
10. Menezes VM, Soares BG, Fontes CJ. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 2006; 2: CD004967.
11. Tobon A, Agudelo CA, Restrepo A. Posaconazole for the treatment of paracoccidioidomycosis: First clinical results. Biomedica 2008; 28: 205.
12. Shikanai-Yasuda MA, Telles Filho FQ, Mendes RP, Colombo AL,Moretti ML. Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop 2006; 39: 297-310 [in Portuguese].
13. Shikanai-Yasuda MA, Benard G, Higaki Y et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med Mycol 2002; 40: 411-417.
14. Marques SA, Dillon NL, Franco MF et al. Paracoccidioidomycosis: A comparative study of the evolutionary serologic, clinical and radiologic results for patients treated with ketoconazole or amphotericin B plus sulfonamides. Mycopathologia 1985; 89: 19-23.
15. Queiroz-Telles F, Goldani LZ, Schlamm HT et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45: 1462-1469.
16. Queiroz-Telles F. Comparative efficacy of cotrimoxazole and itraconazole in the treatment of paracoccidioidomycosis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 27 September 1998, abstract J-142.
17. Marques SA. Paracoccidioidomycosis. Clin Dermatol 2012; 30: 610-615.
18. Jepsen P, Johnsen SP, Gillman MW, Sorensen HT. Interpretation of observational studies. Heart 2004; 90: 956-960.
19. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text, 3rd edn. New York: Springer, 2011.
20. Ressing M, Blettner M, Klug SJ. Data analysis of epidemiological studies: Part 11 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2010; 107: 187-192.
21. Borges SRC. Study of factors that influence the effectiveness of treatment in patients with paracoccidioidomycosis. MSc thesis, Fiocruz, 2010.
22. Do Valle AC, Costa RL, FialhoMonteiro PC et al. Interpretation and clinical correlation of serological tests in paracoccidioidomycosis. Med Mycol 2001; 39: 373-377.
23. Bustamante-Teixeira MT, Faerstein E, Latorre MdR. Survival analysis techniques. Cad Sau? de Pu? blica 2002; 18: 579-594 [in Portuguese].
24. R Development Core Team [homepage on the Internet]. Vienna: R: A language and environment for statistical computing, 2.14; [site updated 2012 June 20; cited 2013 May 2]. Available fromhttp://www.R-project.org10.1093/mmy/myt017.html
25. Paniago AM, Aguiar JI, Aguiar ES et al. Paracoccidioidomycosis: A clinical and epidemiological study of 422 cases observed in Mato Grosso do Sul. Rev Soc Bras Med Trop 2003; 36: 455-459 [in Portuguese].
26. Verli FD, Marinho SA, Souza SC, Figueiredo MA, Yurgel LS. Clinical-epidemiologic profile of paracoccidioidomycosis at the Stomatology Department of Sao Lucas Hospital, Pontificia Universidade Catolica of Rio Grande do Sul. Rev Soc Bras Med Trop 2005; 38: 234-237 [in Portuguese].
27. Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An update. Clin Microbiol Rev 1993; 6: 89-117.
28. Wanke B, Valle AC ( eds). Dynamics Of Infectious And Parasitic Diseases, 1st edn. Rio de Janeiro: Guanabara Koogan, 2005.
29. Noordzij M, Dekker FW, Zoccali C, Jager KJ. Study designs in clinical research. Nephron Clinical Practice 2009; 113: C218-c221.
30. Lortholary O, Denning DW, Dupont B. Endemic mycoses: A treatment update. J Antimicrob Chemother 1999; 43: 321-331.
31. Manns BJ, Baylis BW, Urbanski SJ, Gibb AP, Rabin HR. Paracoccidioidomycosis: Case report and review. Clin Infect Dis 1996; 23: 1026-1032.
32. Benard G. An overview of the immunopathology of human paracoccidioidomycosis. Mycopathologia 2008; 165: 209-221.